Ensitrelvir (fumarate)

Ensitrelvir (fumarate)

CAT N°: 35844
Price:

From 134.00 113.90

Ensitrelvir is an orally bioavailable inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), also known as 3C-like protease (3CLpro), with an IC50 value of 0.013 µM.{67052} It is selective for Mpro over HIV-1 protease and the human proteases caspase-2, chymotrypsin, thrombin, and cathepsin B, -D, -G, and -L (IC50s = >100 µM for all). Ensitrelvir reduces the cytopathic effects of SARS-CoV-2 clinical isolates, including Alpha, Beta, Gamma, Delta, and Omicron strains, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV), in Vero E6 cells expressing human transmembrane serine protease 2 (TMPRSS2; EC50s = 0.29-1.4 µM). Oral administration of ensitrelvir decreases lung viral titers in a mouse model of SARS-CoV-2 Gamma variant infection when administered at doses ranging from 2 to 32 mg/kg at the time of, and 12 hours after, infection.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4(1H,3H)-dione, (2E)-2-butenedioate
  • Correlated keywords
    • 2647530-73-0 S217622 SARSCoV2 HIV1 caspase2 ? ? ? ? SARSCoV MERSCoV TMPRSS 2 Xocova
  • Product Overview:
    Ensitrelvir is an orally bioavailable inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), also known as 3C-like protease (3CLpro), with an IC50 value of 0.013 µM.{67052} It is selective for Mpro over HIV-1 protease and the human proteases caspase-2, chymotrypsin, thrombin, and cathepsin B, -D, -G, and -L (IC50s = >100 µM for all). Ensitrelvir reduces the cytopathic effects of SARS-CoV-2 clinical isolates, including Alpha, Beta, Gamma, Delta, and Omicron strains, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV), in Vero E6 cells expressing human transmembrane serine protease 2 (TMPRSS2; EC50s = 0.29-1.4 µM). Oral administration of ensitrelvir decreases lung viral titers in a mouse model of SARS-CoV-2 Gamma variant infection when administered at doses ranging from 2 to 32 mg/kg at the time of, and 12 hours after, infection.

We also advise you